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Abstract
Objective: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to 
evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of 
children and adults and in patients with acromegaly.
Participants: GRS invited 34 international experts including clinicians, basic scientists, a 
regulatory scientist and physicians from the pharmaceutical industry.
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Evidence: Current literature was reviewed and expert opinion was utilized to establish 
the state of the art and identify current gaps and unmet needs.
Consensus process: Following plenary presentations, breakout groups discussed 
questions framed by the planning committee. The attendees re-convened after each 
breakout session to share the group reports. A writing team compiled the breakout 
session reports into a document that was subsequently discussed and revised by 
participants. This was edited further and circulated for inal review after the meeting. 
Participants from pharmaceutical companies were not part of the writing process.
Conclusions: The clinical endpoint in paediatric GH treatment is adult height with height 
velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible 
clinical endpoint of GH treatment in adult GH-deicient patients (GHDA) and in patients 
with acromegaly. The pragmatic clinical endpoints in GHDA include normalization 
of body composition and quality of life, whereas symptom relief and reversal of 
comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, 
even though it correlates weakly with clinical endpoints in GH treatment, whereas in 
acromegaly, normalization of IGF-I may be related to improvement in mortality. There 
is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in 
relation to GH treatment and in patients with acromegaly.
Introduction
Biological markers (biomarkers) play an essential role 
in the clinical care of patients, drug development and 
regulatory approval. Furthermore, biomarkers are 
linked to surrogate endpoints and clinical endpoints 
(1, 2, 3, 4). The requirement for rigorous procedures 
utilizing biomarkers in drug development is evident and 
recognized (2, 5). The obvious biomarkers of growth 
hormone (GH) action in children and adults are serum 
levels of GH itself and of insulin-like growth factor-I 
(IGF-I). Both are used diagnostically; IGF-I is used to 
monitor the effects of GH replacement in GH deiciency 
(GHD), and both GH and IGF-I are used in the diagnosis 
and management of acromegaly. While serum IGF-I level 
is used as a surrogate endpoint in trials involving GH 
treatment and medical treatment of acromegaly, neither 
GH nor IGF-I has been subject to a structured evaluation 
as biomarkers, nor do we have a comprehensive 
deinition of clinical endpoints for the treatment of 
GH-related disorders. Therefore, there is a need to deine 
clinically relevant endpoints and identify and evaluate 
current and novel surrogate endpoints and biomarkers 
of therapies targeting GH.
The Growth Hormone Research Society (GRS) 
convened a Workshop in Aarhus, Denmark, on November 
15–18, 2017 to review the current state of the ield and 
address key issues regarding the deinition of clinical 
endpoints for GH therapy and treatment of acromegaly, 
to critically evaluate current surrogate endpoints for 
GH therapy and treatment of acromegaly and to discuss 
novel and potential biomarkers of GH action in children 
and adults.
Methods
The structure of this Workshop was adapted from prior 
Workshops organized by GRS (6, 7, 8). Thirty-four 
invited international leaders from twelve countries 
across ive continents participated. These included 
paediatric and adult endocrinologists, basic scientists, a 
European medicines regulator and physicians from the 
pharmaceutical industry. A review of the current status 
of clinical endpoints and biomarkers was written prior to 
the meeting. A planning committee of the GRS comprised 
academic adult and paediatric endocrinologists who 
determined the agenda, selected speakers to summarize 
key relevant topics and formulated the questions for 
discussion.
Following presentations that summarized the 
literature, three breakout groups addressed each topic in 
more detail by discussing the list of questions formulated 
by the planning committee and subsequently agreed upon 
by all participants. All attendees re-convened after each of 
the breakout sessions to share reports from the groups. 
At the end of days 1 and 2, a writing team compiled 
the breakout group reports into a inal document that 
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was discussed and reviewed in its entirety and revised 
by participants on the concluding day. When there was 
no clear agreement by most participants, consensus 
was reached by voting. This draft document was edited 
further for formatting and references, and subsequently 
circulated to the academic attendees for inal review after 
the meeting. Meeting participants from pharmaceutical 
companies, who participated in the Workshop, were not 
part of the writing team and were not present during 
text revision on the inal day, but they were shown the 
manuscript before submission to identify factual errors. 
This report is a concise chronicle of the Workshop and is 
not intended to be an exhaustive review of the literature 
on this topic. It was written utilizing: (1) the content from 
the speaker presentations and the current literature in the 
ield, (2) the combined comments of the breakout groups 
to the questions and (3) the collective remarks of the 
entire group during report-back sessions.
Definitions
The following terms and deinitions, which derive from an 
NIH expert working group (1) were used in the Workshop:
Clinical endpoint: A characteristic or variable that 
relects how a patient feels, functions or survives.
Biomarker: A characteristic that is objectively measured 
and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention.
Surrogate endpoint: A biomarker that is intended to 
substitute for a clinical endpoint. A surrogate endpoint 
is expected to predict beneit (or harm or lack of 
beneit or harm) based on epidemiologic, therapeutic, 
pathophysiologic or other scientiic evidence.
A major emphasis was made on measures of treatment 
eficacy and safety.
Clinical and surrogate endpoints during 
GH treatment
Paediatric GH therapy
Adult height is the ultimate clinical endpoint of GH 
therapy in children (9), although it is recognized that 
normalization of height during childhood, independent 
of eventual height, is an additional goal. A uniform 
deinition of adult height in the context of GH therapy 
in children is not available, but a pragmatic deinition 
used in several trials have been a height gain <2 cm over 
the last 12  months. In clinical practice and in clinical 
trials, change in height velocity (cm/year) or change 
in height standard deviation score (SDS) are used as 
surrogate endpoints of eficacy and to monitor adherence 
to therapy in individual children with GHD (Table 1). In 
children being treated with GH for non-GHD conditions, 
the change in height velocity or height SDS is used 
as surrogate endpoints. In patients with Prader–Willi 
syndrome, although auxological measures are important, 
measures of the metabolic actions of GH are also valuable, 
including change in body mass index (BMI) and body 
composition (10). This also applies to other conditions 
such as children born small for gestational age. Growth 
response during the irst year of GH treatment for short 
Table 1 Current clinical endpoints, surrogate endpoints and biomarkers in GH therapy and acromegaly.
Patients and treatments Clinical eficacy endpoints Surrogate endpoints Biochemical biomarker
Paediatric GH treatment
  GH deiciency Adult height Change in height SDS/growth 
velocity
IGF-I
  GH deiciency in the transition period Body composition Peak bone mass, DXA Z score, LBM, 
and FM
IGF-I
  CRI, Noonan syndrome, SHOX, Turner 
syndrome, SGA, SRS, ISS
Adult height Change in height SDS/growth 
velocity
IGF-I
  Prader–Willi syndrome Body composition
Adult height
Neuro-cognition
Muscle tone
IGF-I
Adult GH treatment Body composition
Quality of life
Anthropometry, DXA Z score, LBM 
and FM
Questionnaires
IGF-I
Acromegaly treatment 
 
Serum IGF-I and GH 
reduction
Symptom relief
IGF-I, GH
Symptom scores 
IGF-I 
 
CRI, chronic renal insuficiency; DXA, dual X-ray absorptiometry; FM, fat mass; IGF-I, insulin-like growth factor I; ISS, idiopathic short stature; LBM, lean 
body mass; SDS, standard deviation score; SGA, small for gestational age; SHOX, short stature homeobox deiciency; SRS, Silver–Russell syndrome.
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stature is correlated with growth rates in subsequent years 
and adult height. Prediction models using auxology, bone 
age and other variables have been advocated as tools for 
individual patient management (10, 11, 12). Measurement 
of body proportions can be helpful in certain subgroup 
of patients, such as cancer survivors receiving spinal 
radiation. Bone age and decrease in growth velocity 
can be used as biomarkers for epiphyseal maturation to 
determine the time at which GH treatment should cease.
Transition from childhood to adult GH 
replacement therapy
At the time when a patient reaches adult height, GHD 
is either reconirmed by retesting or recognised as a life-
long condition based on the underlying pathology. Since 
growth can no longer be used as a biomarker, the clinical 
focus in patients during the transition turns to adult 
endpoints, such as peak bone mass and body composition 
including fat mass and lean body mass (13).
Adult GH replacement
Adult patients are only treated when there is an 
established diagnosis of GHD with the goal of replacing 
the insuficient hormone. Adult GHD is recognized as a 
syndrome with various and multifactorial comorbidities 
affecting different organ systems (14). Therefore, the 
impact of GH therapy cannot be directly correlated 
with a single clinical endpoint. Unlike in paediatric GH 
therapy, where measurement of growth is central to all 
GH-treated patients, the goals of adult GH replacement 
therapy take into consideration age, functional status and 
comorbidities.
Clinical endpoints for GH replacement in adults with 
GHD include body composition and quality of life (QoL). 
Measurement of body composition may include waist 
circumference, dual-energy X-ray absorptiometry (DXA) 
scan for bone mineral density and content (BMD/BMC), 
and where available, fat distribution such as truncal fat 
and lean body mass (Table 1). The routine consultation 
should include patient reported outcomes such as mood, 
motivation, energy levels, physical mobility, activities of 
daily living and employment. Formal questionnaires are 
used in some health systems to determine the eligibility 
for treatment and to monitor response to therapy (15).
A reduction in excess mortality in adult GHD would 
be an ideal clinical endpoint, but such data are unlikely 
to be forthcoming. The information available suggests 
there is an increased mortality in adult patients with 
hypopituitarism including GHD due to cardiovascular 
(CV) disease (16). Therefore, biomarkers for CV risk, 
including blood pressure, visceral fat, lipids and high-
sensitive C-reactive protein (hsCRP), are commonly 
measured.
Safety is monitored by asking about GH side effects, 
including oedema, carpal tunnel syndrome and joint 
pains and via measurement of haemoglobin A1C (HbA1C) 
levels.
Biochemical biomarkers during GH treatment
IGF-I
Serum IGF-I is a biomarker of GH status, often being low in 
GHD and high in GH excess. It is not subject to the diurnal 
variation or pulsatility that is characteristic of endogenous 
GH secretion. GH has direct, IGF-I-independent actions 
as well as indirect effects mediated through hepatic and 
local tissue IGF-I production. Serum IGF-I, which mainly 
relects liver-derived IGF-I, is suppressed during catabolic 
conditions and has signiicant within-individual and 
inter-assay variability (7, 17, 18). Despite these limitations, 
measurement of serum IGF-I levels is currently used as a 
biomarker for GH action (Table 1).
Use of serum IGF-I in paediatric GH treatment
Measurement of serum IGF-I during GH therapy in 
children is used as a biomarker for adherence. Its 
relationship to growth rate and inal height is inluenced 
by other variables including bone age, birth length and 
nutritional status, and it therefore has a limited role as 
a marker of eficacy. This is particularly true for subsets 
of non-GHD patients, who may have some degree of 
associated GH and IGF-I insensitivity (19). Failure to raise 
serum IGF-I concentrations during GH treatment may be 
an early indication of GH insensitivity and could warrant 
further evaluation and alternative treatments (20).
The increase in IGF-I with GH treatment is dose 
dependent and dosing can be adjusted with a goal of 
attaining an IGF-I within the normal range. However, as 
noted earlier, serum IGF-I has proved disappointing as a 
direct correlate to clinical outcome, but it is currently the 
best option available. This highlights the need for new 
biomarkers to predict the eficacy and safety of therapy in 
individual patients.
IGF-I is also used as a long-term safety marker during 
GH treatment. This practice is based on an extrapolation 
from epidemiologic data in healthy adult populations, and 
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meta-analyses and life course data in patients with 
acromegaly that have shown an increase in morbidity and 
mortality of subjects having upper-normal or consistently 
elevated IGF-I levels (6). Nevertheless, modestly and 
transiently elevated serum IGF-I concentrations in 
GH-treated paediatric patients have not been linked 
to adverse effects. There are no accepted guidelines for 
IGF-I levels during GH treatment in GHD children, but 
where possible, IGF-I should be maintained within the 
normal range, although modest elevations above +2 S.D. 
may be acceptable under certain circumstances. During 
the treatment of non-GHD states, in order to achieve an 
acceptable growth response, IGF-I may transiently be above 
the normal range; however, the safety implications are 
unknown.
Use of serum IGF-I in transition and adult GHD
During GH replacement, the GH dose in adults is titrated 
to target IGF-I levels within the normal range. Serum IGF-I 
levels do not correlate well with clinical endpoints, but 
may help guiding dose titration. Despite the limitations 
noted earlier, it is used as a biomarker for safety. GH 
dose during the transition period is typically in-between 
paediatric and adult doses, with adjustment primarily 
based on serum IGF-I, just as in adult patients (13).
Insulin-like growth factor-binding protein 3 (IGFBP-
3), acid-labile subunit (ALS) and bioactive IGF-I
IGF-binding protein 3 (IGFBP-3) is the major carrier protein 
for IGF-I in serum. There are limited data indicating that 
IGFBP-3 predicts GH responsiveness or safety. However, 
epidemiologic data suggest that high IGFBP-3 levels may 
reduce the IGF-I-associated risk of certain cancers (21). 
Therefore, additional studies measuring IGF-I, IGFBP-3 
and their molar ratio during GH therapy as safety markers 
may be useful. Bioactive IGF-I as measured by the kinase-
receptor activation (KIRA) assay is a useful research tool and 
accurately relects changes in GH-responsive proteins (22). 
However, this assay is labour-intensive and costly and at the 
current time cannot be utilized in large clinical studies or 
clinical practice. The ALS is a GH-dependent protein, but its 
usefulness in clinical practice has not been established (23).
Biomarkers in the context of long-acting 
growth hormone (LAGH) products
Neither daily GH administration nor LAGH recapitulate 
the natural pattern of GH secretion. Unlike daily 
GH, steady state IGF-I levels do not occur with LAGH 
products. Each of these novel products has a unique 
pharmacodynamic (PD) proile, which means that they 
cannot be considered as a homogenous group. Modelling 
approaches based on PD measurement can be used to 
indicate the optimal time for serum IGF-I measurement 
for dose titration purposes (24). The relationship between 
IGF-I and IGFBP-3 may also be different among the 
various LAGH products (25). Since some of these agents 
are GH analogues as opposed to authentic GH, they may 
potentially exert other biological effects that could affect 
safety and eficacy. This suggests there may be a need to 
develop biomarkers that are speciic for a given LAGH 
product. Given the differences among these products, 
speciic pharmacovigilance programmes may be essential 
for each LAGH product (8).
Clinical endpoints and biomarkers 
in acromegaly
Acromegaly is diagnosed by a combination of clinical 
signs and symptoms, pituitary MRI, and increased serum 
IGF-I and GH levels. Therapeutic options include surgery, 
medical therapy and radiotherapy. There remain a number 
of clinical controversies, which might be addressed by 
improved biomarkers.
Key clinical endpoints in acromegaly are amelioration 
of the signs, symptoms and comorbidities associated 
with tumour mass effect and excess GH secretion, with 
the goal of normalization of life expectancy. Composite 
scoring/grading systems for acromegaly disease activity, 
which combine clinical, histopathology, tumour 
characteristics and biochemical parameters, have been 
developed. However, they have not yet been adapted 
and validated for individual patient care (26, 27). A 
disease-related QoL questionnaire as well as a symptom-
scoring instrument have been developed and validated, 
and they may serve as independent markers for patient-
related outcomes (28, 29).
Anthropometric measures such as changes in inger 
thickness measured by ring size, lean body mass and fat 
mass have been assessed using DXA and CT in clinical 
trials, but these methods have not been applied uniformly 
in clinical care. This indicates a need for validated tools 
adapted for patient management.
Serum IGF-I and GH levels are established biomarkers 
of disease activity in acromegaly and elevated levels 
have been associated with excess mortality. IGF-I is the 
most commonly measured biomarker for determining 
the success of treatment (Table 1). GH can be valuable in 
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assessing the effect of pituitary surgery and is an index 
of completion of tumour removal. Clinical practice varies 
regarding the method used to evaluate GH; random 
measurements, oral glucose suppression of GH and ‘day 
curves’ with timed measurements across the day have all 
been used (30).
It can be dificult to determine whether treated 
patients with discordant IGF-I and GH levels are 
optimally controlled. There are a number of reasons 
for this discrepancy, such as oral oestrogen treatment, 
nutritional status, history of pituitary radiotherapy, assay 
variability and inadequate reference ranges. In addition, 
there are therapy-speciic changes that can lead to this 
discrepancy. For example, during somatostatin analogue 
treatment, there is a reduction in serum IGF-I that is not 
associated with a proportional reduction of GH (31). 
Measurement of GH is not helpful during treatment with 
GH receptor antagonists (32). Consideration of these 
factors should be taken into account before making 
therapeutic decisions.
Measurement of serum IGFBP-3 or ALS does not 
provide additional value beyond serum IGF-I in the 
routine management of patients with acromegaly.
Treatment should be monitored according to the 
treatment-speciic side effects. Monitoring of glucose 
metabolism and CV risk factors is standard of care for 
patients with acromegaly (33). Potent therapies for 
acromegaly may result in overtreatment, as manifested as 
subnormal levels of serum IGF-I.
Novel biomarkers – an unmet need
GH and IGF-I have been used as biomarkers for several 
decades, and they have been essential to the management 
of GH-treated patients and patients with acromegaly (17, 
34). Improvements in assay sensitivity and speciicity 
and standardisation over the subsequent years have been 
helpful, but markers more closely linked to eficacy and 
safety endpoints are still needed (35).
Paediatric indications
In paediatrics, there is currently an unmet need for 
better predictors of GH treatment eficacy in relation 
to linear growth response, metabolic beneit and safety. 
There is a need for biomarkers that relect therapeutic 
response in speciic tissues such as the growth plate and 
skeleton in a variety of disorders associated with short 
stature. (36).
Adult GH replacement
Serum IGF-I primarily relects GH action in the liver 
(37), but its relationship to clinically meaningful eficacy 
endpoints such as measures of body composition is 
limited in individual patients (38). Other GH-responsive 
biomarkers can be measured, such as bone turnover 
markers, but the long-term value of their measurement 
in clinical practice is unknown. There is a major need for 
biomarkers that relect the diverse effects of GH therapy 
on carbohydrate, protein and lipid metabolism as well as 
QoL in a dose-dependent manner.
Acromegaly
The ideal biochemical biomarker of eficacy should 
accurately relect disease activity and be independent of 
treatment modality. As with adult GHD, there is a need 
for biomarkers that relect improvement of metabolic 
status during therapy. There is also a need for a biomarker 
to predict optimal response to therapy, especially in 
circumstances when GH and IGF-I are discordant.
Potential candidates
A number of GH-responsive markers including matrix 
metalloproteinases 2 and 9, vascular endothelial growth 
factor, isoforms of apolipoprotein A-1 and haptoglobin and 
afamin have been identiied (39, 40, 41). Their usefulness 
as biomarkers should be established in future studies. GH 
doping detection strategies have highlighted proteins such 
as procollagen Type III N-peptide and other bone markers 
in serum that may have utility in acromegaly management 
in the future (42, 43). A pharmacogenomic study has 
identiied genetic biomarkers of responsiveness to GH 
treatment of children with GHD or Turner syndrome, which 
seems a promising future tool (44). In addition, circulating 
levels of a degradation fragment of type X collagen, which 
is a by-product of endochondral ossiication, may provide a 
tool to monitor growth in paediatric patients (45).
Conclusion
Adult height remains the clinical endpoint of GH 
treatment in paediatric patients, and height velocity 
during the irst and second year after treatment initiation 
is useful surrogate endpoints. In adult GHD patients, 
a reduction in truncal fat mass is typically the main 
clinical eficacy endpoint for regulatory purposes, but 
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improvement in QoL and physical itness are also used 
in clinical practice. Lowering of elevated IGF-I levels in 
combination with symptom relief are eficacy endpoints 
used both for regulatory approval of novel drugs for 
acromegaly treatment and in clinical practice. Serum IGF-I 
is above all the most widely used biochemical biomarker 
during GH treatment as well as in acromegaly (Table 1); 
nonetheless, serum IGF-I correlates only weakly with 
clinical endpoints of eficacy.
There is an unmet need for novel biomarkers within the 
ield of GH treatment and acromegaly. Systems medicine 
approaches using genomics, epigenomics, metabolomics 
and proteomics may facilitate selection of patients for 
therapy and improve prediction of clinical endpoints. 
Therefore, such approaches deserve further study, and the 
collection of suitable samples for biobanking should be 
considered in relevant clinical trials. The identiication 
of novel biomarkers for action of GH requires access 
to samples from prospective controlled interventional 
trials. At present, numerous large-scale studies are being 
undertaken to examine the eficacy of LAGH preparations 
and new treatments for acromegaly, which provide the ideal 
opportunity to prospectively identify such novel markers.
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